Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02755597 · ClinicalTrials.gov registry record · Phase 3
A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
A Phase 3 study of Relapsed/Refractory Multiple Myeloma, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 291
- Enrollment target
- 20
- Study locations
NCT02755597 is a Phase 3 study of Relapsed/Refractory Multiple Myeloma that has completed, run by AbbVie. The registered enrollment target is 291 participants, above the 148-participant average among 9 other Relapsed/Refractory Multiple Myeloma trials with a reported enrollment target (97% higher). The trial reports 20 study locations across 14 states.
The verdict
NCT02755597, a Phase 3 study of Relapsed/Refractory Multiple Myeloma, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 291 participants
- Enrollment target
- 20
- Study locations
Study Summary
This was a Phase 3, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of venetoclax plus bortezomib and dexamethasone in participants with relapsed or refractory multiple myeloma who are considered sensitive or naïve to proteasome inhibitors and received 1 to 3 prior lines of therapy for multiple myeloma.
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG Dexamethasone
- DRUG Bortezomib
- DRUG Placebo for venetoclax
Study Locations (20)
New South Wales
- Royal Prince Alfred Hospital /ID# 149108 - Camperdown
- Concord Repatriation General Hospital /ID# 149106 - Concord
- Liverpool Hospital /ID# 149110 - Liverpool
Victoria
- Box Hill Hospital /ID# 149112 - Box Hill
- Peter MacCallum Cancer Ctr /ID# 149107 - Melbourne
- Alfred Health /ID# 150085 - Melbourne
Colorado
- Rocky Mountain Regional VA Medical Center/Eastern Colorado Health Care System /ID# 156524 - Aurora
- Univ of Colorado Cancer Center /ID# 149130 - Aurora
Western Australia
- Fiona Stanley Hospital /ID# 148967 - Murdoch
- Perth Blood Institute Ltd /ID# 148966 - Nedlands
North Carolina
- Duke Cancer Center /ID# 149099 - Durham
Ohio
- Gabrail Cancer Center Research /ID# 149098 - Canton
Queensland
- Royal Brisbane and Women's Hospital /ID# 149105 - Herston
South Australia
- The Queen Elizabeth Hospital /ID# 149104 - Woodville South
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 291 participants |
| Start Date | 2016-07-11 |
| Est. Completion | 2022-08-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02755597
The ClinicalTrials.gov registry entry for NCT02755597 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 291 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 148-participant average among 9 other Relapsed/Refractory Multiple Myeloma trials with a reported enrollment target (97% higher). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed/Refractory Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Venetoclax is the first listed.
NCT02755597 reports 20 study locations spanning 14 distinct geographic areas - top geographies include New South Wales, Victoria, Colorado.
Frequently Asked Questions
What is clinical trial NCT02755597 about?
NCT02755597 is a clinical study titled "A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy". This was a Phase 3, multicenter, randomized, double blind, placebo-controlled study evaluating the efficacy and safety of venetoclax plus bortezomib and dexamethasone in participants with relapsed or refractory multiple myeloma who are considered sensitive or naïve to proteasome inhibitors and recei...
What is the current status of trial NCT02755597?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 291 participants. The study started on 2016-07-11. Estimated completion is 2022-08-15.
What conditions does trial NCT02755597 study?
This clinical trial studies the following conditions: Relapsed/Refractory Multiple Myeloma.
What interventions are being tested in trial NCT02755597?
The interventions under investigation include: Venetoclax (DRUG), Dexamethasone (DRUG), Bortezomib (DRUG), Placebo for venetoclax (DRUG).
Who is sponsoring clinical trial NCT02755597?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02755597 being conducted?
This trial has 20 study locations across Colorado, North Carolina, Ohio, New South Wales, Queensland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed/Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
COMPLETED · Phase 3
-
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
RECRUITING · Phase 1
-
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 2
-
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.